Botulinum neurotoxins: fundamentals for the facial plastic surgeon

American Journal of Otolaryngology - Head and Neck Medicine and Surgery

Volumn 28, Issue 4, 2007, Pages 260-266

  Adelson, Robert Todd ^a  

^a UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A;

ARTICLE; CLINICAL PRACTICE; CLOSTRIDIA; DRUG MECHANISM; DRUG POTENCY; FACE SURGERY; HISTORY OF MEDICINE; HUMAN; IMMUNE RESPONSE; MEDICAL RESEARCH; NEUROMUSCULAR SYNAPSE; NONHUMAN; PRIORITY JOURNAL; SURGEON; SUSTAINED RELEASE PREPARATION; WRINKLE;

ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; FACIAL PARALYSIS; HUMANS; POSTOPERATIVE COMPLICATIONS; SURGERY, PLASTIC; TREATMENT OUTCOME;

EID: 34250894911     PISSN: 01960709     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjoto.2006.09.002     Document Type: Article

References (71)

1. Munchau A., and Bhatia K.P. Uses of botulinum toxin injection in medicine today. BMJ 320 (2000) 161-165
2. Zimbler M.S., and Nassif P.S. Adjunctive applications for botulinum toxin in facial aesthetic surgery. Facial Plast Surg Clin North Am (2003) 477-482
3. Lamanna C. The most poisonous poison. Science 130 (1969) 763-772
4. American Society of Plastic Surgeons-Statistics for 2005. http://www.plasticsurgery.org/public_education/2005Statistics.cfm. Accessed on 6/15/2006.
5. American Academy of Facial Plastic and Reconstructive Surgery-Statistics for 2005. http://www.aafprs.org/media/stats_polls/m_stats.html. Accessed on 6/15/2006.
6. Lam S.M. The basic science of botulinum toxin. Facial Plast Surg Clin North Am 11 (2003) 431-438
7. Jost W.H., and Kohl A. Botulinum toxin: evidence-based medicine criteria in rare indications. J Neurol 248 Suppl (2001) S39-S44
8. Aoki K.R. Botulinum toxin: a successful therapeutic protein. Curr Med Chem 11 23 (2004) 3085-3092
9. Neuenschwander M.C., Pribitkin E.A., and Sataloff R.T. Botulinum toxin in otolaryngology: a review of its actions and opportunities for use. Ear Nose Throat J 79 10 (2000) 788-801
10. Wenzel R.G. Pharmacology of botulinum neurotoxin serotype A. Am J Health Syst Pharm 61 Suppl (2004) S5-S10
11. Scott A.B. Development of botulinum toxin therapy. Dermatol Clin 22 (2004) 131-133
12. Erbguth N. Historical aspects of botulinum toxin. Neurology 53 (1999) 1850-1853
13. Van Ermengem E.P. Classics in infectious disease: a new anaerobic bacillus and its relation to botulism. Rev Infect Dis 4 (1979) 701-719
14. Gunn R.A. Botulism toxin: from van Ermengem to the present. Rev Infect Dis 1 4 (1979) 720-721
15. Thakker M.M., and Rubin P.A.D. Pharmacology and clinical applications of botulinum toxins A and B. Int Ophthalmol Clin 44 3 (2004) 147-163
16. Blitzer A., and Slica L. Botulinum toxin: basic science and clinical use in otolaryngology. Laryngoscope 111 (2001) 218-226
17. Schantz E.J., and Johnson E.A. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med 40 (1997) 317-327
18. Scott A.B., Rosenbaum A., and Collins C. Pharmacologic weakening of extraocular muscles. Invest Ophthalmol 12 12 (1973) 924-927
19. Scott A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87 10 (1980) 1044-1049
20. Tsui J.K., Eisen A., Mak E., et al. A pilot study on the use of botulinum toxin in spasmodic torticollis. Can J Neurol Sci 12 4 (1985) 314-316
21. Carruthers A., and Carruthers J. History of the cosmetic use of botulinum A exotoxin. Dermatol Surg 24 (1998) 1168-1170
22. Carruthers A., and Carruthers J. Cosmetic uses of botulinum A exotoxin. Adv Dermatol 12 (1997) 325-347 [discussion 348]
23. Carruthers J.D., and Carruthers J.A. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18 1 (1992) 17-21
24. Carrruthers J.D., Lowe N.J., Menter A., et al. Double-blind, placebo-controlled study of the safety and efficacy of botulinum toxin type A for patients with glabellar lines. Plast Reconstr Surg 112 (2003) 1089-1098
25. Blitzer A., Binder W.J., Aviv J.E., et al. The management of hyperfunctional facial lines with botulinum toxin. Arch Otolaryngol Head Neck Surg 123 (1997) 389-392
26. Keen M., Blitzer A., Aviv J., et al. Botulinum toxin A for hyperkinetic facial lines: results of a double-blind, placebo-controlled study. Plast Reconstr Surg 94 1 (1994) 94-99
27. Rohrich R.J., Janis J.E., Faigen S., et al. The cosmetic use of botulinum toxin. Plast Reconstr Surg 112 Suppl (2003) S177-S187
28. Matarasso A., and Deva A.K. Botulinum toxin. Plast Reconstr Surg 109 (2002) 1191-1197
29. Setler P.E. Therapeutic use of botulinum toxins: background and history. Clin J Pain 18 (2002) S119-S124
30. Simpson L.L. A comparison of the pharmacological properties of clostridium botulinum type C1 and C2 toxins. J Pharmacol Exp Ther 223 3 (1982) 695-701
31. Simpson L.L. The action of botulinal toxin. Rev Infect Dis 1 4 (1979) 656-659
32. Gonnering R.S. Pharmacology of botulinum toxin. Int Ophthalmol Clin 33 4 (1993) 203-226
33. Barth H., Roebling R., Fritz M., et al. The binary clostridium botulinum C2 toxin as a protein delivery system. J Biol Chem 277 7 (2002) 5074-5081
34. Richard J.F., Petit L., Gibert M., et al. Bacterial toxins modifying the actin cytoskeleton. Int Microbiol 2 3 (1999) 185-194
35. Klein A.W. Contraindications and complications with the use of botulinum toxin. Clin Dermatol 22 (2004) 66-75
36. Bajjalieh S.M. Synaptic vesicle docking and fusion. Curr Opin Neurobiol 9 (1999) 321-328
37. Coffield J.A., Bakry N., Zhang R.D., et al. In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches. J Pharmacol Exp Ther 280 3 (1997) 1489-1498
38. Glogau R.G. Review of the use of botulinum toxin for hyperhidrosis and cosmetic purposes. Clin J Pain 18 Suppl (2002) S191-S197
39. Blasi J., Chapman E.R., and Link E. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP25. Nature 365 (1993) 160-163
40. Foran P., Lawrence G.W., Shone C.C., et al. Botulinum neurotoxin C1 cleaves both syntaxin and SNAP-25 in intact and permeabilized chromaffin cells: correlation with its blockade of catecholamine release. Biochemistry 35 8 (1996) 2630-2636
41. Angaut-Petit D., Molgo J., Comella J.X., Faille L., et al. Terminal sprouting in mouse neuromuscular junctions poisoned with botulinum type A toxin: morphological and electrophysiological features. Neuroscience 37 3 (1990) 799-808
42. Pamphlett R. Early terminal and nodal sprouting of motor axons after botulinum toxin. J Neurol Sci 92 2-3 (1989) 181-192
43. Harris C.P., Alderson K., Nebeker J., et al. Histologic features of human orbicularis oculi treated with botulinum A toxin. Arch Ophthalmol 109 3 (1991) 393-395
44. Eleopra R., Tugnoli V., Rosetto O., et al. Different time courses of recovery after poisoning with botulinum neurotoxin serotypes A and E in humans. Neurosci Lett 256 (1998) 135-138
45. Eleopra R., Tugnoli V., Quatrale R., et al. Different types of botulinum toxin in humans. Mov Disord 19 Suppl 8 (2004) S53-S59
46. Mezaki T., Kaji R., and Kohara N. Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study. Neurology 45 (1995) 506-508
47. Sadick N.S., and Matarasso S.L. Comparison of botulinum toxins A and B in the treatment of facial rhytides. Dermatol Clin 22 (2004) 221-226
48. Sloop R.R., Cole B.A., and Escutin R.O. Human response to botulinum toxin injection: type B compared with type A. Neurology 49 1 (1997) 189-194
49. Critchfield J. Considering the immune response to botulinum toxin. Clin J Pain 18 Suppl (2002) S133-S141
50. Kessler K.R., Skutta M., and Benecke R. Long-term treatment of cervical dystonia with botulinum toxin A: efficacy, safety, and antibody frequency. J Neurol 246 4 (1999) 265-274
51. Carruthers A., and Carruthers J. Toxins 99, new information about the botulinum neurotoxins. Dermatol Surg 26 (2000) 174-176
52. Pearce L.B., Borodic G.E., Johnson E.A., et al. The median paralysis unit: a more pharmacologically relevant unit of biologic activity for botulinum toxin. Toxicon 33 2 (1995) 217-227
53. Carruthers J., Faigen S., and Matarasso S.L. Consensus recommendations on the use of botulinum toxin type A in facial aesthetics. Plast Reconstr Surg 114 Suppl (2004) 1S-22S
54. Yamauchi P.S., and Lowe N.J. Botulinum toxin types A and B: comparison of efficacy, duration, and dose-ranging studies for the treatment of facial rhytides and hyperhidrosis. Clin Dermatol 22 1 (2004) 34-39
55. Botox Package Insert, Allergan, Inc. www.botox.com/site/professionals/home.asp
56. Hexsel D.M., De Almeida A.T., Rutowitsch M., et al. Multicenter, double-blind study of the efficacy of injections with botulinum toxin type A reconstituted up to six consecutive weeks before application. Dermatol Surg 29 5 (2003) 523-529
57. Myobloc Package Inset. Solstice Neurosciences, Inc. http://www.myobloc.com
58. Baumann L., and Black L. Botulinum toxin type B (Myobloc). Dermatol Surg 29 5 (2003) 496-500
59. Flynn T.C. Myobloc. Dermatol Clin 22 (2004) 207-211
60. Dysport Package Information, Ipsen Limited; http://www.ipsen.ltd.uk.
61. Markey A.C. Dysport. Dermatol Clin 22 (2004) 213-219
62. Flynn T.C., and Clark R.E. Botulinum toxin type B (MYOBLOC) versus botulinum toxin type A (BOTOX) frontalis study: rate of onset and radius of diffusion. Dermatol Surg 29 5 (2003) 519-522
63. Alam M., Dover J.S., and Arndt K.A. Pain associated with injection of botulinum toxin A exotoxin reconstituted using isotonic sodium chloride with and without preservative. Arch Dermatol 138 (2002) 510-514
64. Van Laborde S., Dover J.S., Moore M., et al. Reduction in injection pain with botulinum toxin type B further diluted using saline with preservative: a double-blind, randomized controlled trial. J Am Acad Dermatol 48 6 (2003) 875-877
65. Callaway J.E. Botulinum toxin type B (Myobloc): pharmacology and biochemistry. Clin Dermatol 22 (2004) 23-28
66. Hsu T.S., Dover J.S., and Arndt K.A. Effect of volume and concentration on the diffusion of botulinum exotoxin A. Arch Dermatol 140 11 (2004) 1351-1354
67. Mantell A.M. Dilution, storage and electromyographic guidance in the use of botulinum toxins. Dermatol Clin 22 (2004) 135-136
68. Almeida De Trindade A.R., Kadunc B.V., Di Chiacchio N., et al. Foam during reconstitution does not affect the potency of botulinum toxin type A. Dermatol Surg 29 5 (2003) 530-531
69. Sarifakioglu N., and Sarifakioglu E. Evaluating the effects of ice application on the pain felt during botulinum toxin type-A injections: a prospective, randomized, single-blind controlled trial. Ann Plast Surg 53 6 (2004) 543-546
70. Klein A.W., and Mantell A. Electromyographic guidance in injecting botulinum toxin. Dermatol Surg 24 (1998) 1184-1186
71. Vartanian A.J., and Dayan D.H. Complications of botulinum toxin A use in facial rejuvenation. Facial Plast Surg Clin North Am 11 (2003) 48-492